| Date Filed | Type | Description |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/05/2022 |
SC 13D/A
| CAXTON CORP reports a 0% stake in Strongbridge Biopharma plc |
| 01/05/2022 |
4
| CDK ASSOCIATES, L.L.C. (10% Owner) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Disposed of 8,060,682 shares
@ $0
Disposed of 2,220,000 options to buy
@ $2.5, valued at
$5.6M
|
|
| 10/25/2021 |
SC 13D/A
| Growth Equity Opportunities Fund III, LLC has filed a Schedule 13D for Strongbridge Biopharma plc |
| 10/15/2021 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 10/07/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/07/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/07/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/06/2021 |
4
| Wilhoit Scott L. (Chief Commercial Officer) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Disposed/sold 109,510 shares
@ $0
Disposed/sold 649,000 options to buy
@ $0 |
|
| 10/06/2021 |
4
| Kollender Richard S (President and CFO) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Disposed/sold 234,229 shares
@ $0
Disposed/sold 544,918 options to buy
@ $0 |
|
| 10/06/2021 |
4
| Cohen Fredric J. (Chief Medical Officer) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Disposed/sold 160,408 shares
@ $0
Disposed/sold 868,818 options to buy
@ $0 |
|
| 10/06/2021 |
4
| JOHNSON JOHN (CEO) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Disposed/sold 610,092 shares
@ $0
Disposed/sold 495,724 options to buy
@ $0 |
|
| 10/06/2021 |
4
| Steineger Hilde H (Director) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Disposed/sold 64,258 shares
@ $0
Disposed/sold 154,918 options to buy
@ $0 |
|
| 10/06/2021 |
4
| Steen Marten (Director) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Disposed/sold 64,151 shares
@ $0
Disposed/sold 154,918 options to buy
@ $0 |
|
| 10/06/2021 |
4
| SHERMAN JEFFREY W (Director) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Disposed/sold 64,258 shares
@ $0
Disposed/sold 140,000 options to buy
@ $0 |
|
| 10/06/2021 |
4
| Kong Garheng (Director) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Disposed/sold 63,993 shares
@ $0
Disposed/sold 154,385 options to buy
@ $0 |
|
| 10/06/2021 |
4
| GILL DAVID N (Director) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Disposed/sold 78,058 shares
@ $0 |
|
| 10/06/2021 |
4
| LONG STEPHEN J (Chief Legal Officer) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Disposed/sold 117,793 shares
@ $0
Disposed/sold 714,045 options to buy
@ $0 |
|
| 10/05/2021 |
4
| Wilhoit Scott L. (Chief Commercial Officer) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Paid exercise price by delivering 27,515 shares
@ $2.06, valued at
$56.7k
|
|
| 10/05/2021 |
4
| LONG STEPHEN J (Chief Legal Officer) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Paid exercise price by delivering 49,307 shares
@ $2.06, valued at
$101.6k
|
|
| 10/05/2021 |
4
| Kollender Richard S (President and CFO) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Paid exercise price by delivering 64,791 shares
@ $2.06, valued at
$133.5k
|
|
| 10/05/2021 |
4
| Cohen Fredric J. (Chief Medical Officer) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Paid exercise price by delivering 51,548 shares
@ $2.06, valued at
$106.2k
|
|
| 10/05/2021 |
4
| Steen Marten (Director) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Paid exercise price by delivering 17,763 shares
@ $2.06, valued at
$36.6k
|
|
| 10/05/2021 |
4
| JOHNSON JOHN (CEO) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Paid exercise price by delivering 334,868 shares
@ $2.06, valued at
$689.8k
|
|
| 10/05/2021 |
4
| Steineger Hilde H (Director) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Paid exercise price by delivering 17,763 shares
@ $2.06, valued at
$36.6k
|
|
| 10/05/2021 |
4
| SHERMAN JEFFREY W (Director) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Paid exercise price by delivering 17,763 shares
@ $2.06, valued at
$36.6k
|
|
| 10/05/2021 |
4
| Kong Garheng (Director) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Paid exercise price by delivering 17,763 shares
@ $2.06, valued at
$36.6k
|
|
| 10/05/2021 |
4
| GILL DAVID N (Director) has filed a Form 4 on Strongbridge Biopharma plc|
Txns:
| Paid exercise price by delivering 17,763 shares
@ $2.06, valued at
$36.6k
|
|
| 10/05/2021 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 10/05/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/05/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/05/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/05/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/05/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
|